Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial
Charles S Fuchs,Kohei Shitara,Maria Di Bartolomeo,Sara Lonardi,Salah-Eddin Al-Batran,Eric Van Cutsem,David H Ilson,Maria Alsina,Ian Chau,Jill Lacy,Michel Ducreux,Guillermo Ariel Mendez,Alejandro Molina Alavez,Daisuke Takahari,Wasat Mansoor,Peter C Enzinger,Vera Gorbounova,Zev A Wainberg,Susanna Hegewisch-Becker,David Ferry,Ji Lin,Roberto Carlesi,Mayukh Das,Manish A Shah,RAINFALL Study Group,Alexander V Luft,Nina A Karaseva,Rubén Dario Kowalyszyn,Carlos Alberto Hernandez,Tibor Csoszi,Ferdinando De Vita,Per Pfeiffer,Naotoshi Sugimoto,Judit Kocsis,Andràs Csilla,Gyorgy Bodoky,Georgina Garnica Jaliffe,Svetlana Protsenko,Ayman Madi,Elzbieta Wojcik,Baruch Brenner,Gunnar Folprecht,Tomasz Sarosiek,Katriina Johanna Peltola,Peter Bono,Hubert Ayala,Giuseppe Aprile,Cardellino Giovanni Gerardo,Fidel David Huitzil Melendez,Alfredo Falcone,Francesco Di Costanzo,Moustapha Tehfe,Laurent Mineur,Pilar García Alfonso,Radka Obermannova,Hélène Senellart,Russell Petty,Leslie Samuel,Peter Istvan Acs,Maen Abdelkarim Hussein,Marina N Nechaeva,F L G Erdkamp,Elizabeth Won,Johanna Chock Bendell,Javier Gallego Plazas,Sylvie Lorenzen,Bohuslav Melichar,Miguel Angel Escudero,Denis Pezet,Jean-Marc Phelip,Diego Lucas Kaen,James A Jr Reeves,Federico Longo Muñoz,Srinivasan Madhusudan,Carlo Barone,Luis Enrique Fein,Angel Gomez Villanueva,Mohamed Hebbar,Jana Prausova,Laura Visa Turmo,Joana Vidal Barrull,Mette Karen Nytoft Yilmaz,Alex Beny,H M W Van Laarhoven,Brian Anthony DiCarlo,Taito Esaki,Kazumasa Fujitani,Karen Geboes,Ravit Geva,Shigenori Kadowaki,Stephen Leong,Nozomu Machida,Moses Sundar Raj,Francisco Javier Ramirez Godinez,Agnes Ruzsa,Hugo Ford,William E Lawler,Nicolas Robert Maisey,Jiri Petera,Einat Shacham-Shmueli,Isabelle Sinapi,Kensei Yamaguchi,Hiroki Hara,Joseph Thaddeus Beck,Maria Błasińska-Morawiec,Ricardo Villalobos Valencia,Thierry Alcindor,Madhuri Bajaj,Scott Berry,Christina Maria Gomez,Daniel Dammrich,Ravindranath Patel,Julien Taieb,A J Ten Tije,Ronald L Burkes,Fernando Cabanillas,Irfan Firdaus,Cynthia Coo Chua,Shuichi Hironaka,Ralf-Dieter Hofheinz,Howard J Lim,Marianne Nordsmark,Bela Piko,Udit Verma,Jonathan Wadsley,Seigo Yukisawa,Francisco Gutiérrez Delgado,Crystal S Denlinger,Raija Kallio,Joanna Pikiel,Joanna Wojcik-Tomaszewska,Christine Brezden-Masley,Raymond Woo-Jun Jang,Jana Pribylova,Daisuke Sakai,Maria Alejandra Bartoli,A Cats,M I Grootscholten,Robert Andrew Dichmann,Hugo Hool,Walid Shaib,Akihito Tsuji,Marc Van den Eynde,Hector Velez-Cortez,Timothy R Asmis
DOI: https://doi.org/10.1016/S1470-2045(18)30791-5
Abstract:Background: VEGF and VEGF receptor 2 (VEGFR-2)-mediated signalling and angiogenesis can contribute to the pathogenesis and progression of gastric cancer. We aimed to assess whether the addition of ramucirumab, a VEGFR-2 antagonist monoclonal antibody, to first-line chemotherapy improves outcomes in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma. Methods: For this double-blind, randomised, placebo-controlled, phase 3 trial done at 126 centres in 20 countries, we recruited patients aged 18 years or older with metastatic, HER2-negative gastric or gastro-oesophageal junction adenocarcinoma, an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and adequate organ function. Eligible patients were randomly assigned (1:1) with an interactive web response system to receive cisplatin (80 mg/m2, on the first day) plus capecitabine (1000 mg/m2, twice daily for 14 days), every 21 days, and either ramucirumab (8 mg/kg) or placebo on days 1 and 8, every 21 days. 5-Fluorouracil (800 mg/m2 intravenous infusion on days 1-5) was permitted in patients unable to take capecitabine. The primary endpoint was investigator-assessed progression-free survival, analysed by intention to treat in the first 508 patients. We did a sensitivity analysis of the primary endpoint, including a central review of CT scans. Overall survival was a key secondary endpoint. This study is registered with ClinicalTrials.gov, number NCT02314117. Findings: Between Jan 28, 2015, and Sept 16, 2016, 645 patients were randomly assigned to receive ramucirumab plus fluoropyrimidine and cisplatin (n=326) or placebo plus fluoropyrimidine and cisplatin (n=319). Investigator-assessed progression-free survival was significantly longer in the ramucirumab group than the placebo group (hazard ratio [HR] 0·753, 95% CI 0·607-0·935, p=0·0106; median progression-free survival 5·7 months [5·5-6·5] vs 5·4 months [4·5-5·7]). A sensitivity analysis based on central independent review of the radiological images did not corroborate the investigator-assessed difference in progression-free survival (HR 0·961, 95% CI 0·768-1·203, p=0·74). There was no difference in overall survival between groups (0·962, 0·801-1·156, p=0·6757; median overall survival 11·2 months [9·9-11·9] in the ramucirumab group vs 10·7 months [9·5-11·9] in the placebo group). The most common grade 3-4 adverse events were neutropenia (85 [26%] of 323 patients in the ramucirumab group vs 85 [27%] of 315 in the placebo group), anaemia (39 [12%] vs 44 [14%]), and hypertension (32 [10%] vs 5 [2%]). The incidence of any-grade serious adverse events was 160 (50%) of 323 patients in the ramucirumab group and 149 (47%) of 315 patients in the placebo group. The most common serious adverse events were vomiting (14 [4%] in the ramucirumab group vs 21 [7%] in the placebo group) and diarrhoea (11 [3%] vs 19 [6%]). There were seven deaths in each group, either during study treatment or within 30 days of discontinuing study treatment, which were the result of treatment-related adverse events. In the ramucirumab group, these adverse events were acute kidney injury, cardiac arrest, gastric haemorrhage, peritonitis, pneumothorax, septic shock, and sudden death (n=1 of each). In the placebo group, these adverse events were cerebrovascular accident (n=1), multiple organ dysfunction syndrome (n=2), pulmonary embolism (n=2), sepsis (n=1), and small intestine perforation (n=1). Interpretation: Although the primary analysis for progression-free survival was statistically significant, this outcome was not confirmed in a sensitivity analysis of progression-free survival by central independent review, and did not improve overall survival. Therefore, the addition of ramucirumab to cisplatin plus fluoropyrimidine chemotherapy is not recommended as first-line treatment for this patient population. Funding: Eli Lilly and Company.